| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_361c6223f33de77431dc880348294a7c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 |
| filingDate |
2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434d98a1ceff3eab095884b141893a7e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575ae645b209afd6ef29f8d5166d1981 |
| publicationDate |
2018-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3265102-A1 |
| titleOfInvention |
Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| abstract |
A compound of the structure (A), or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein. |
| priorityDate |
2015-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |